Mankind Pharma has entered into a definitive agreement to acquire a 70% stake in Belgium-based biotechnology company Armed Cell Therapeutics (ACTx) for EUR 48 million, marking its strategic entry into next-generation CAR-T therapies for cancer. The acquisition represents a step in the pharmaceutical company’s long-term strategy to build a global, innovation-led business focused on advanced therapies.

Through its subsidiary, Mankind Pharma (Netherlands) B.V., the company will gain access to ACTx’s research pipeline, which includes programmes targeting non-Hodgkin lymphoma and small cell lung cancer. The partnership is expected to strengthen Mankind Pharma’s presence in advanced cancer therapy research.

Mankind Pharma to Invest EUR 48 Million for 70% Stake

Under the definitive agreement, Mankind Pharma will invest EUR 48 million to acquire a 70% stake in Armed Cell Therapeutics, a biotechnology company incorporated in Belgium.

The transaction will provide Mankind Pharma with exposure to next-generation CAR-T research and an opportunity to expand its presence in complex therapeutic areas.

Key highlights of the acquisition include:

Investment: EUR 48 million

Stake to be acquired: 70%

Acquired company: Armed Cell Therapeutics B.V.

Headquarters: Belgium

Lead research programmes: Non-Hodgkin lymphoma and small cell lung cancer

Research focus: Next-generation armed CAR-T therapies, including approaches to generate CAR-T cells in vivo

The company’s research and development activities are led by experienced teams based in the United States and Europe.

What Are Next-Generation CAR-T Therapies?

CAR-T, or chimeric antigen receptor T-cell therapy, is an approach that modifies a patient’s T cells to recognise and attack cancer cells. CAR-T therapies have transformed treatment for certain blood cancers, although challenges such as treatment resistance, limited persistence of CAR-T cells and cancer relapse remain.

Armed Cell Therapeutics is developing next-generation CAR-T therapies designed to address some of these challenges.

Its approach involves engineering CAR-T cells with additional payloads intended to strengthen and sustain their anti-tumour activity. The company is also exploring strategies that target more than one cancer antigen, with the aim of reducing the ability of cancer cells to evade treatment.

These programmes remain part of the company’s research and development pipeline; their potential benefits will depend on further development and clinical evaluation.

Armed Cell Therapeutics Targets Two Key Cancer Areas

Armed Cell Therapeutics has identified two lead areas for its next-generation CAR-T research.

1. Non-Hodgkin lymphoma

Non-Hodgkin lymphoma is a group of cancers that affect the lymphatic system. Although CAR-T therapies have changed treatment options for certain patients, relapse remains a challenge. ACTx is developing programmes intended to improve the effectiveness and durability of CAR-T responses.

2. Small cell lung cancer

Small cell lung cancer is an aggressive form of lung cancer with limited effective treatment options. ACTx’s research pipeline includes programmes focused on this cancer type, reflecting its broader interest in extending CAR-T approaches beyond established applications in blood cancers.

The programmes are part of ongoing research and should not be interpreted as approved or commercially available treatments.

Mankind Pharma Strengthens Its Innovation-Led Growth Strategy

The Mankind Pharma CAR-T therapy acquisition aligns with the company’s ambition to expand its research capabilities and build a global pipeline of differentiated therapies.

According to Arjun Juneja, Chief Operating Officer of Mankind Pharma, the investment is an initial step towards building a global pipeline of breakthrough therapies. He highlighted the company’s interest in accessing advanced scientific platforms, experienced leadership and opportunities to develop next-generation CAR-T candidates.

Mankind Pharma has an established presence in India’s pharmaceutical formulations and consumer healthcare sectors. Its portfolio spans acute and chronic therapeutic areas, including anti-infectives, cardiovascular, gastrointestinal, antidiabetic, neuro/CNS, gynaecology and respiratory treatments.

The company also has a substantial domestic distribution network, 32 manufacturing facilities in India and seven dedicated research and development facilities supported by more than 740 scientists, according to the press release.

The Armed Cell Therapeutics investment adds a new dimension to this established pharmaceutical business by creating exposure to advanced cell therapy research.

Experienced Leadership at Armed Cell Therapeutics

Armed Cell Therapeutics was founded by professionals with experience in drug development, cell therapy and biotechnology businesses.

Its leadership includes:

Dr. Paul Stoffels: Chair of the Board and former Chief Executive Officer of Galapagos, as well as former Vice Chairman and Chief Scientific Officer of Johnson & Johnson.

Dr. John Mellors: Chief Scientific Officer, Distinguished Professor of Medicine at the University of Pittsburgh and former senior executive at Galapagos.

Peter Verhaeghe: Corporate finance and life sciences lawyer, and former Chair of argenx.

The company’s operations include its Belgian headquarters, activities in the Netherlands, research and pre-clinical operations in Pittsburgh, United States, and early-development CAR-T activities across Europe, Asia and the United States.

What the Acquisition Means for Mankind Pharma

The acquisition marks Mankind Pharma’s entry into next-generation CAR-T therapy research and supports its ambition to participate in global pharmaceutical innovation.

By acquiring a majority stake in ACTx, Mankind Pharma gains access to a specialised biotechnology pipeline focused on cancer treatment research. The partnership also brings together Mankind Pharma’s pharmaceutical capabilities and ACTx’s focus on engineered cell therapies.

The future impact of the transaction will depend on the development of ACTx’s research programmes, clinical outcomes and the regulatory pathway for potential therapies.

Conclusion

The Mankind Pharma CAR-T therapy acquisition represents a strategic move into advanced cancer research, with a EUR 48 million investment for a 70% stake in Armed Cell Therapeutics. With research programmes targeting non-Hodgkin lymphoma and small cell lung cancer, the partnership expands Mankind Pharma’s exposure to next-generation cell therapies and supports its broader innovation-led growth strategy.